$32.28
0.83% today
Nasdaq, Feb 28, 05:22 pm CET
ISIN
US47103J1051
Symbol
JANX
Sector
Industry

Janux Therapeutics Inc Stock price

$32.01
-11.53 26.48% 1M
-13.16 29.13% 6M
-21.53 40.21% YTD
-17.74 35.66% 1Y
+14.73 85.24% 3Y
+6.86 27.28% 5Y
+6.86 27.28% 10Y
Nasdaq, Closing price Thu, Feb 27 2025
-0.59 1.81%
ISIN
US47103J1051
Symbol
JANX
Sector
Industry

Key metrics

Market capitalization $1.85b
Enterprise Value $1.22b
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 93.15
P/S ratio (TTM) P/S ratio 141.77
P/B ratio (TTM) P/B ratio 2.55
Revenue growth (TTM) Revenue growth 54.12%
Revenue (TTM) Revenue $13.05m
EBIT (operating result TTM) EBIT $-85.96m
Free Cash Flow (TTM) Free Cash Flow $-37.82m
Cash position $658.03m
EPS (TTM) EPS $-1.18
P/E forward negative
P/S forward 171.40
EV/Sales forward 113.68
Short interest 24.75%
Show more

Is Janux Therapeutics Inc a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,809 stocks worldwide.

Janux Therapeutics Inc Stock Analysis

Unlock Scores for Free

Analyst Opinions

15 Analysts have issued a Janux Therapeutics Inc forecast:

13x Buy
87%
2x Hold
13%

Analyst Opinions

15 Analysts have issued a Janux Therapeutics Inc forecast:

Buy
87%
Hold
13%

Financial data from Janux Therapeutics Inc

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '24
+/-
%
13 13
54% 54%
100%
- Direct Costs 2.08 2.08
14% 14%
16%
11 11
65% 65%
84%
- Selling and Administrative Expenses 35 35
61% 61%
268%
- Research and Development Expense 60 60
3% 3%
458%
-84 -84
14% 14%
-643%
- Depreciation and Amortization 2.08 2.08
14% 14%
16%
EBIT (Operating Income) EBIT -86 -86
14% 14%
-659%
Net Profit -61 -61
3% 3%
-464%

In millions USD.

Don't miss a Thing! We will send you all news about Janux Therapeutics Inc directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Janux Therapeutics Inc Stock News

Neutral
Business Wire
about 20 hours ago
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics, Inc. (Nasdaq: JANX) (Janux), a clinical-stage biopharmaceutical company developing a broad pipeline of novel immunotherapies by applying its proprietary technology to its Tumor Activated T Cell Engager (TRACTr) and Tumor Activated Immunomodulator (TRACIr) platforms, today reported financial results for the fourth quarter and full year en...
Neutral
Business Wire
about one month ago
SAN DIEGO--(BUSINESS WIRE)---- $JANX--Janux Therapeutics Promotes Zachariah McIver, D.O., Ph.D. to Chief Medical Officer.
Positive
Seeking Alpha
about 2 months ago
Janux Therapeutics' leading candidate, JANX007, shows high efficacy and safety in Phase 1 trials for metastatic castration-resistant prostate cancer, targeting a multi-billion dollar TAM. Janux's TRACTr and TRACIr platforms differentiate it in immunotherapy by enabling tumor-activated bispecific therapeutics for precise cancer targeting with minimal systemic toxicity. JANX's robust balance shee...
More Janux Therapeutics Inc News

Company Profile

Janux Therapeutics, Inc. operates preclinical stage biopharmaceutical company which engages in developing therapeutics based on the Tumor Activated T Cell Engager platform technology. The company was founded in June 2017 and is headquartered in La Jolla, CA.

Head office United States
CEO David Campbell
Employees 64
Founded 2017
Website www.januxrx.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today